MCID: LMY002
MIFTS: 51

Leiomyoma

Categories: Cancer diseases, Muscle diseases

Aliases & Classifications for Leiomyoma

MalaCards integrated aliases for Leiomyoma:

Name: Leiomyoma 12 73 54 44 15
Leiomyomatous Neoplasm 12
Leiomyomatous Tumor 12
Uterine Fibroids 70
Fibroid Tumor 70
Leiomyomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:127
MeSH 44 D007889
NCIt 50 C3157
SNOMED-CT 67 702978006
UMLS 70 C0023267 C0042133

Summaries for Leiomyoma

Disease Ontology : 12 A cell type benign neoplasm that is a benign tumor of smooth muscle cells.

MalaCards based summary : Leiomyoma, also known as leiomyomatous neoplasm, is related to leiomyoma, uterine and bizarre leiomyoma, and has symptoms including pelvic pain An important gene associated with Leiomyoma is HMGA2 (High Mobility Group AT-Hook 2), and among its related pathways/superpathways are Pathways in cancer and TGF-beta Signaling Pathways. The drugs Lidocaine and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 A leiomyoma, also known as fibroids, is a benign smooth muscle tumor that very rarely becomes cancer... more...

Related Diseases for Leiomyoma

Diseases related to Leiomyoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 886)
# Related Disease Score Top Affiliating Genes
1 leiomyoma, uterine 32.9 RAD51B PGR HMGA2 GNRH1 FH ESR1
2 bizarre leiomyoma 32.8 PGR MED12 FH ESR1 ACTC1
3 benign metastasizing leiomyoma 32.6 VIM PGR DES CYP19A1 ACTC1
4 leiomyoma cutis 32.6 MED12 FH COL4A6
5 lung leiomyoma 32.6 PGR ESR1
6 cellular leiomyoma 32.5 MME MED12 DES
7 bladder leiomyoma 32.3 VIM GNRH1 CD34
8 liver leiomyoma 32.3 PGR ESR1 CD34
9 colon leiomyoma 32.3 MED12 FH CD34
10 subserous uterine fibroid 32.3 PGR CYP19A1
11 dartoic leiomyoma 32.1 FH CD34
12 orbital leiomyoma 32.1 S100A1 GNRH1
13 leiomyomatosis 32.0 PGR MED12 GNRH1 FH ESR1 COL4A6
14 breast leiomyoma 32.0 PGR MME CD34
15 vulvar leiomyoma 31.9 PGR MME HMGA2 ESR1 CD34
16 leiomyosarcoma 31.7 VIM S100A1 PGR MED12 HMGA2 FH
17 rare tumor 31.5 DES ACTC1
18 myofibroma 31.4 S100A1 DES CD34
19 spindle cell sarcoma 31.0 VIM DES CD34 ACTC1
20 mesenchymal cell neoplasm 31.0 MME HMGA2 CD34
21 ovarian cyst 31.0 GNRH1 ESR2 CYP19A1
22 endometriosis 31.0 PGR GNRH1 ESR2 ESR1 CYP19A1
23 intravenous leiomyomatosis 30.9 PGR MME MED12 HMGA2 ESR1 DES
24 myoma 30.8 PGR MME MED12 HMGA2 GNRH1 FH
25 adenomyosis 30.8 PGR MME GNRH1 ESR2 ESR1 CYP19A1
26 lymphangioleiomyomatosis 30.8 PGR GNRH1 ESR1 DES
27 pleomorphic lipoma 30.8 PGR HMGA2 CD34
28 fibroma 30.8 VIM S100A1 DES CD34 ACTC1
29 intracranial meningioma 30.7 PGR ESR1
30 vaginal discharge 30.7 PGR GNRH1 ESR1 CYP19A1
31 gastrointestinal stromal tumor 30.7 VIM S100A1 DES CD34 ACTC1
32 lipomatosis, multiple 30.7 HMGA2 DES CD34
33 prostatic hypertrophy 30.7 PGR ESR1 CYP19A1
34 diffuse peritoneal leiomyomatosis 30.6 PGR MED12 GNRH1 CYP19A1
35 endometrial hyperplasia 30.6 PGR ESR2 ESR1 CYP19A1
36 infertility 30.6 PGR GNRH1 ESR2 ESR1 CYP19A1
37 hemangioma 30.6 VIM PGR CD34 ACTC1
38 pneumothorax 30.6 VIM PGR GNRH1
39 in situ carcinoma 30.6 PGR ESR1 CYP19A1
40 neurilemmoma 30.5 VIM S100A1 DES CD34 ACTC1
41 cystadenoma 30.5 PGR MME FH
42 fibromatosis 30.5 VIM DES ACTC1
43 granular cell tumor 30.5 VIM S100A1 DES
44 endometrial adenocarcinoma 30.5 PGR ESR2 ESR1
45 smooth muscle tumor 30.5 VIM S100A1 PGR MME MED12 HMGA2
46 myxoid leiomyosarcoma 30.4 PGR ACTC1
47 neurofibroma 30.4 VIM S100A1 CD34 ACTC1
48 malignant mesenchymoma 30.4 DES CD34
49 liposarcoma 30.4 VIM HMGA2 DES CD34
50 hemangiopericytoma, malignant 30.3 VIM DES CD34 ACTC1

Graphical network of the top 20 diseases related to Leiomyoma:



Diseases related to Leiomyoma

Symptoms & Phenotypes for Leiomyoma

UMLS symptoms related to Leiomyoma:


pelvic pain

GenomeRNAi Phenotypes related to Leiomyoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00154-A 9.89 HMGA2
2 Decreased viability GR00221-A-1 9.89 ESR1
3 Decreased viability GR00221-A-2 9.89 ESR1
4 Decreased viability GR00221-A-4 9.89 ESR1
5 Decreased viability GR00249-S 9.89 DPT MED12 RAD51B S100A1 VIM
6 Decreased viability GR00386-A-1 9.89 COX6C DPT ESR1 PGR S100A1
7 Decreased viability GR00402-S-2 9.89 ESR1 MED12 VIM
8 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 ESR1 ESR2 FH RAD51B

MGI Mouse Phenotypes related to Leiomyoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.07 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
2 cardiovascular system MP:0005385 10.06 ACTC1 CYP19A1 DES ESR1 ESR2 MED12
3 homeostasis/metabolism MP:0005376 9.97 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
4 muscle MP:0005369 9.61 ACTC1 CAPN6 CYP19A1 DES ESR1 ESR2
5 normal MP:0002873 9.36 ACTC1 COL4A6 CYP19A1 ESR1 ESR2 GNRH1

Drugs & Therapeutics for Leiomyoma

Drugs for Leiomyoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ethanol Approved Phase 4 64-17-5 702
4
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
7
Calcium carbonate Approved, Investigational Phase 4 471-34-1
8
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
9
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Ferrous fumarate Approved Phase 4 141-01-5
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
14
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
15
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
16
Zinc oxide Approved Phase 4 1314-13-2
17
Tocopherol Approved, Investigational Phase 4 1406-66-2
18
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
22
Prilocaine Approved Phase 4 721-50-6 4906
23
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
24
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
25
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
26
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
27
Misoprostol Approved Phase 4 59122-46-2 5282381
28
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
29
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432 71715
30
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
31
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
32
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
33
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
36
Dienogest Approved Phase 4 65928-58-7
37
Tranexamic Acid Approved Phase 4 1197-18-8 5526
38
Goserelin Approved Phase 4 65807-02-5 47725 5311128
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
41
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
42
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
43
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
44
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
46
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
47
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
48
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
50
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051

Interventional clinical trials:

(show top 50) (show all 361)
# Name Status NCT ID Phase Drugs
1 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
2 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
5 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
6 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
7 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
8 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
9 Ulipristal Versus Gonadotropin-releasing Hormone Agonists Prior to Laparoscopic Myomectomy: a Double Blind Randomized Controlled Trial Unknown status NCT02288130 Phase 4 GnRHa;Ulipristal
10 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
11 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
12 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
13 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
14 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
15 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
16 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
17 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Completed NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
18 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
19 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
20 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
21 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
22 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
23 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
24 Deep Sedation in Spontaneously Breathing Patients Combined With Local Anesthesia Versus General Anesthesia in Gynecological Patients at Same Day Surgical at Hospitalsenheden Horsens Completed NCT01412632 Phase 4 Remifentanil, propofol and citanest
25 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
26 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
27 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
28 Effect of Transversus Abdominal Plane Block Using Liposomal Bupivacaine Versus Standard Bupivacaine for Open Myomectomy: A Prospective Randomized Control Trial Recruiting NCT04272086 Phase 4 Bupivacaine;Bupivacaine liposome;normal saline
29 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
30 Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy: a Randomized Controlled Trial Recruiting NCT04482959 Phase 4 Carbetocin;Sodium chloride 0.9%
31 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Extracts of Plants Pregnenolone & Pyridoxal Phosphate for Treating Uterine Fibroids in Women of Reproductive Age and Women Pregnancy. Active, not recruiting NCT04762316 Phase 4 PP6
32 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
33 Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Not yet recruiting NCT04364581 Phase 4 Letrozole;Placebo
34 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
35 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
36 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
37 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
38 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Terminated NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
39 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Terminated NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
40 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Unknown status NCT02942537 Phase 2, Phase 3
41 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
42 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
43 Effect of Dexmedetomidine on Stress Study of Pituitrin in Laparoscopic Hysteromyoma Surgery Unknown status NCT03524950 Phase 3 Dexmedetomidine
44 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
45 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
46 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Unknown status NCT03483142 Phase 3 Misoprostol;Placebos
47 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
48 A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques Completed NCT00365989 Phase 3
49 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
50 Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids Completed NCT01141062 Phase 3

Search NIH Clinical Center for Leiomyoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Leuprolide
Leuprolide Acetate

Cochrane evidence based reviews: leiomyoma

Genetic Tests for Leiomyoma

Anatomical Context for Leiomyoma

MalaCards organs/tissues related to Leiomyoma:

40
Uterus, Smooth Muscle, Breast, Small Intestine, Prostate, Kidney, Liver

Publications for Leiomyoma

Articles related to Leiomyoma:

(show top 50) (show all 12367)
# Title Authors PMID Year
1
Progesterone is essential for maintenance and growth of uterine leiomyoma. 54 61
20375184 2010
2
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 61 54
20414849 2010
3
Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. 54 61
20414841 2010
4
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. 61 54
19464003 2010
5
Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. 61 54
19328471 2010
6
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. 61 54
19906824 2010
7
Mayer-Rokitansky-Kustner Hauser syndrome complicated by either uterine leiomyoma or ovarian tumor. 61 54
20178550 2010
8
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 54 61
20124487 2010
9
Association of N-terminal pro B-type natriuretic peptide and sex hormone-binding globulin in non-obese peri- and postmenopausal women. 54 61
19945451 2010
10
Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. 54 61
19741209 2010
11
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 61 54
19135657 2010
12
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 61 54
19700613 2009
13
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 54 61
19808856 2009
14
Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. 54 61
19851199 2009
15
A leiomyoma presenting as an exophytic periurethral mass: a case report and review of the literature. 54 61
19573833 2009
16
High aromatase expression in uterine leiomyoma tissues of African-American women. 61 54
19240151 2009
17
Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. 61 54
19176543 2009
18
Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. 54 61
19179429 2009
19
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 54 61
19151755 2009
20
Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. 54 61
18980243 2009
21
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole. 61 54
18523791 2009
22
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 61 54
18249392 2009
23
Genistein suppresses spontaneous oviduct tumorigenesis in quail. 61 54
20155619 2009
24
Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk. 61 54
18691687 2008
25
Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. 61 54
18853184 2008
26
Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. 54 61
18166184 2008
27
Treatment of symptomatic uterine leiomyoma with letrozole. 54 61
18854113 2008
28
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 61 54
19012097 2008
29
Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience. 54 61
18710984 2008
30
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 54 61
18565690 2008
31
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 54 61
18701604 2008
32
[Fibroblast growth factor gene expression in uterine leiomyomas]. 54 61
18819464 2008
33
Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. 61 54
18580309 2008
34
Differential metabolic consequences of fumarate hydratase and respiratory chain defects. 61 54
18313410 2008
35
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). 61 54
18164802 2008
36
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. 54 61
18448745 2008
37
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 54 61
18403645 2008
38
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 61 54
18281245 2008
39
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. 61 54
18216291 2008
40
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. 61 54
18182446 2008
41
[Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors]. 54 61
18359707 2008
42
Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. 61 54
19083394 2008
43
A limited immunocytochemical panel for the distinction of subepithelial gastrointestinal mesenchymal neoplasms sampled by endoscopic ultrasound-guided fine-needle aspiration. 61 54
18208801 2008
44
Expression of sex hormone-binding globulin, oxytocin receptor, caveolin-1 and p21 in leiomyoma. 61 54
17952758 2008
45
Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. 54 61
19024011 2008
46
Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population. 61 54
18390078 2008
47
Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. 54 61
18089606 2007
48
"Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. 54 61
18059218 2007
49
Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. 61 54
17785366 2007
50
Early growth response gene-1 plays a pivotal role in down-regulation of a cohort of genes in uterine leiomyoma. 54 61
17975260 2007

Variations for Leiomyoma

Expression for Leiomyoma

Search GEO for disease gene expression data for Leiomyoma.

Pathways for Leiomyoma